Key Drivers
- Strong Liquidity
- Persistent Cash Burn
- Minimal Revenue
AIAI Summary
ROIV is now an execution-driven biotech: its $3.9B cash balance can fund LISRAYA's launch and mosliciguat Phase 3, but a ~$25B valuation already assumes strong uptake and continued clinical success, making launch traction and Phase 3 replication the decisive catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Cash Burn
- •Minimal Revenue
ROIV's strong liquidity and low leverage are overshadowed by steep losses, heavy cash burn, minimal revenue, and an exceptionally difficult-to-justify valuation.
Price Behavior
Key Price Behavior Insights:
- •Early September surge
- •$41 resistance
- •$39.50 support
ROIV remains constructive over the last month, but holding $39.50–$39.60 is critical after its sharp early-September surge and pullback from $41.81, with a break lower risking a move toward the mid-$34s.
Sharp jump from the mid-$34s to above $41 in early
Sentiment & News
Key News Insights:
- •LISRAYA Launch
- •Mosliciguat Progress
- •Pipeline Expansion
Roivant's FDA-approved LISRAYA launch and positive mosliciguat Phase 2 data strengthen its commercial and late-stage growth outlook.
The updates are positive for Roivant, supporting near-term revenue potential and reinforcing investor confidence in its pipeline
Similar Companies in Healthcare
Other companies in the same sector with AI ratings